Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
AssigneesAres Trading S.A., ZymoGenetics, Inc., Mayo Foundation for Medical Education and Research
InventorsHerve Broly, Arnaud Ythier, Eric Sievers, Sharon J. Busby, Jan Öhrström, Ivan Nestorov, Stephen M. Ansell
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for treatment of B-cell malignancies, including non-Hodgkin's lymphoma, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.
Claims19
A method for treatment of non-Hodgkin's lymphoma in a patient in need of such treatment comprising administering to the patient a composition comprising a fusion molecule selected from the group consisting of:
- 1) a fusion molecule comprising:
- (i) TACI extracellular domain wherein said TACI extracellular domain consists of the sequence of SEQ ID NO:
- 1, and (ii) a human immunoglobulin-constant domain;
- 2) a fusion molecule comprising amino acids 30-110 of SEQ ID NO:
- 1 and a human immunoglobulin-constant domain;
- 3) a fusion molecule consisting of amino acids 30-110 of SEQ ID NO:
- 1 and a human immunoglobulin-constant domain;
- and
- 4) a fusion molecule consisting of amino acids 30-110 of SEQ ID NO:
- 1 and the human immunoglobulin-constant domain of SEQ ID NO:2;
- wherein said composition is administered in an amount from 0.01 mg per 1 kg of patient's body weight to 10 mg per 1 kg of patient's body weight and wherein said composition is administered 5 times during a 4-week interval followed by administration of the composition on a weekly basis at least during 2 more additional weeks, and wherein said composition is administered subcutaneously or intravenously.
A method for treatment of non-Hodgkin's lymphoma in a patient in need of such treatment comprising administering to the patient a composition comprising a fusion molecule selected from the group consisting of:
- 1) a fusion molecule comprising amino acids 30-110 of SEQ ID NO:
- 1 and a human immunoglobulin-constant domain;
- 2) a fusion molecule consisting of amino acids 30-110 of SEQ ID NO:
- 1 and a human immunoglobulin-constant domain;
- and
- 3) a fusion molecule consisting of amino acids 30-110 of SEQ ID NO:
- 1 and the human immunoglobulin-constant domain of SEQ ID NO:2;
- wherein said composition is administered in an amount from 0.01 mg per 1 kg of patient's body weight to 10 mg per 1 kg of patient's body weight and wherein said composition is administered 5 times during a 4-week interval followed by administration of the composition on a weekly basis at least during 2 more additional weeks, and wherein said composition is administered in route other than oral subcutaneously or intravenously.
Dependencies are inferred from the claim text.